Corsair Capital Management, L.P. Gamida Cell Ltd. Transaction History

Corsair Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.04 - $0.46 $9,434 - $108,494	-235,857 Reduced 76.8%	71,260 $2,000
Q4 2023 Feb 14, 2024	BUY	$0.25 - $1.02 $37,538 - $153,155	150,152 Added 95.66%	307,117 $125,000
Q3 2023 Nov 13, 2023	BUY	$0.85 - $1.87 $48,420 - $106,524	56,965 Added 56.97%	156,965 $161,000
Q2 2023 Aug 14, 2023	BUY	$0.73 - $2.37 $73,000 - $237,000	100,000 New	100,000 $193,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Corsair Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Corsair Capital Management, L.P. with notifications on news.